 |
Abdom Radiol (NY)
- QIN S, Luo H, Hong Y, Fu C, et al
Evaluation of T1 and T2 mapping for non-invasive assessment of HER2 and PD-L1
expression in bladder cancer.
Abdom Radiol (NY). 2026 Mar 9. doi: 10.1007/s00261-026-05390.
PubMed
Abstract available
- TUCKER J, Sharma V, Johnson M, Hibbert R, et al
Safety and Diagnostic Yield of Percutaneous Urinary Bladder Tumor Biopsy.
Abdom Radiol (NY). 2026;51:1444-1449.
PubMed
Abstract available
ACS Nano
- GAO Y, Yang F, Yin L, Wang W, et al
A Redox-Responsive Selenium-Containing Nanomedicine Enables Dual Antioxidant
System Inhibition to Overcome Platinum Resistance and Enhance Immunotherapy in
Bladder Cancer.
ACS Nano. 2026 Mar 10. doi: 10.1021/acsnano.5c21831.
PubMed
Abstract available
Adv Mater
- SU Y, Wu J, Deng Z, Luo Y, et al
In Vivo Target Drug Enrichment Based on Spatiotemporal Acoustic Node Modulation
(STANM) for Bladder Cancer Treatment.
Adv Mater. 2026 Mar 10:e17740. doi: 10.1002/adma.202517740.
PubMed
Abstract available
Aging (Albany NY)
- GONG Z, He Y, Mi X, Li C, et al
Complement and coagulation cascades pathway-related signature as a predictor of
immunotherapy in metastatic urothelial cancer.
Aging (Albany NY). 2023;15:9479-9498.
PubMed
Abstract available
Anal Chem
- ZHANG J, Guo F, Zhu J, He Z, et al
Ultrasensitive Electrochemiluminescence Immunosensor for Bladder Marker Human
Complement Factor H-Related Protein Detection.
Anal Chem. 2023;95:11440-11448.
PubMed
Abstract available
Ann Surg Oncol
- SRETENOVIC M, Bumbasirevic U, Bojanic N, Durutovic O, et al
Prognostic Value of Preoperative Anemia on Survival and Recurrence in Patients
with Bladder Carcinoma Treated by Radical Cystectomy.
Ann Surg Oncol. 2026;33:3743-3751.
PubMed
Abstract available
- WANG Y, Wu N, Zhang F, Zhang S, et al
The Comprehensive Complication Index for Assessing Short-Term Complications of
Urothelial Carcinoma with Variant Histology: A Patient-Based Study.
Ann Surg Oncol. 2026;33:3688-3697.
PubMed
Abstract available
- LONGONI M, Le QC, Falkenbach F, Marmiroli A, et al
The Effect of Pelvic Lymph Node Dissection on Cancer-Specific Mortality in
Partial Cystectomy According to Eligibility Criteria.
Ann Surg Oncol. 2026;33:3680-3687.
PubMed
Abstract available
Arch Esp Urol
- AKIN Y, Yorulmaz EM, Gorgel SN, Ozcan S, et al
Who is Next? Impact of Systemic Immune-Inflammation Index and De Ritis Ratio for
Predicting 90-Day Survival after Salvage Cystectomy in Advanced Bladder Cancer.
Arch Esp Urol. 2026;79:66-72.
PubMed
Abstract available
- SARI H, Celik S, Yorukoglu K, Celebi I, et al
Ankaferd versus Immunotherapeutics and Chemotherapeutics in Bladder Cancer.
Arch Esp Urol. 2026;79:58-65.
PubMed
Abstract available
Asian J Pharm Sci
- FAN G, Luo X, Li K, Zhang Z, et al
Development and preclinical evaluation of a novel FGFR3-targeted antibody-drug
conjugate in bladder cancer.
Asian J Pharm Sci. 2025;20:101095.
PubMed
Abstract available
Asian J Urol
- LIU W, Xiao J, Zou J, He Z, et al
Recurrence and prevention strategies for non-muscle-invasive bladder cancer: A
comprehensive review.
Asian J Urol. 2026;13:11-23.
PubMed
Abstract available
Asian Pac J Cancer Prev
- NUR BUDAYA T, Seputra KP, Susianti H, Aditya Hutama S, et al
Diagnostic Value of Rabbit-Derived 47 kDa Epitope-Based Antibodies as a Detection
and Evaluation Method for Bladder Cancer.
Asian Pac J Cancer Prev. 2026;27:911-920.
PubMed
Abstract available
Biochem Biophys Res Commun
- ANDO K, Kurashina R, Motoi N, Iizuka T, et al
Positive regulatory loop of platelet-derived growth factor DD-induced STAT3
activation is associated with poor prognosis in advanced urothelial carcinoma.
Biochem Biophys Res Commun. 2023;676:165-170.
PubMed
Abstract available
Biochim Biophys Acta Mol Basis Dis
- ZHANG Q, Hong Y, He C, Guo R, et al
Oncogenic epigenetic factor EP300 is a potential therapeutic target for bladder
carcinoma.
Biochim Biophys Acta Mol Basis Dis. 2026;1872:168182.
PubMed
Abstract available
Biosens Bioelectron
- ZHANG Y, Liu L, Yang B, Wu Q, et al
Electron transfer-driven ultrathin nanozyme synergizes with nucleic acid
amplification for bladder cancer screening.
Biosens Bioelectron. 2026;303:118580.
PubMed
Abstract available
BJU Int
- BRYAN RT, Patel K, Ward DG
The nascent role of circulating tumour DNA in the management of
non-muscle-invasive bladder cancer.
BJU Int. 2026 Mar 3. doi: 10.1111/bju.70217.
PubMed
- FERNANDEZ-MARDOMINGO A, Subiela JD, Artiles Medina A, Krajewski W, et al
Impact of re-transurethral resection of bladder staging on risk stratification of
high-grade T1 non-muscle-invasive bladder cancer across European Association of
Urology 2021 risk groups.
BJU Int. 2026 Mar 3. doi: 10.1111/bju.70207.
PubMed
Abstract available
- DAY E, Bizzarri FP, Waine E, Martin R, et al
Contemporary practice patterns in female radical cystectomy: results of a UK and
Ireland survey.
BJU Int. 2026;137:708-715.
PubMed
Abstract available
- PIAZZA P, Barretta A, Bravi CA, Mottaran A, et al
Impact of cumulative smoking exposure on morbidity after robot-assisted radical
cystectomy.
BJU Int. 2026;137:684-689.
PubMed
Abstract available
BJUI Compass
- ISTAMULOV M, Eriksson H, Abuhasanein S
Standardized care pathway reshaped the diagnostic and therapeutic landscape of
urinary bladder cancer. A 15-year population-based study.
BJUI Compass. 2026;7:e70179.
PubMed
Abstract available
Bladder Cancer
- MALSHY K, Messing EM
Circulating tumor DNA-guided adjuvant immunotherapy in muscle-invasive bladder
cancer.
Bladder Cancer. 2026;12:23523735261429862.
PubMed
- SUPERDOCK M, Wobker SE, Carmicheal I, Kim WY, et al
Computational pathology in bladder cancer: A scoping review.
Bladder Cancer. 2026;12:23523735251413333.
PubMed
Abstract available
BMC Cancer
- GAO WB, Yu JJ
Celldetect test performance in monitoring bladder cancer recurrence after
transurethral resection.
BMC Cancer. 2026 Feb 28. doi: 10.1186/s12885-026-15797.
PubMed
BMJ Case Rep
- PRIETO MATIENZO L, Fischer-Straub A, Perera M, Babst C, et al
Follicular lymphoma of the urachus.
BMJ Case Rep. 2026;19:e267211.
PubMed
Abstract available
Can J Urol
- DONMEZ K, Yorulmaz EM, Candemir E, Ozcan S, et al
Unusual metastatic patterns of urologic malignancies: a case series and
literature review.
Can J Urol. 2026;33:211-219.
PubMed
Abstract available
- AKKAD A, Bruyere F, Bourgi A
Uretero-enteric strictures after cystectomy: revealing the modifiable risk
factors.
Can J Urol. 2026;33:155-163.
PubMed
Abstract available
- ZHAN M, Zhou Z, Zhang J, Wang X, et al
Artificial intelligence in urological malignancy diagnosis and prognosis: current
status and future prospects.
Can J Urol. 2026;33:35-49.
PubMed
Abstract available
Cancer Cell
- CHEN C, An M, Zheng H, Pang M, et al
B cells disrupt tertiary lymphoid structure formation and suppress anti-tumor
immunity.
Cancer Cell. 2026;44:551-566.
PubMed
Abstract available
Cancer Cell Int
- LI P, Li L, Li Z, Wang S, et al
Correction: Annexin A1 promotes the progression of bladder cancer via regulating
EGFR signaling pathway.
Cancer Cell Int. 2026;26:119.
PubMed
Cancer Discov
-
Strategy to Analyze Urine Tumor DNA Predicts Outcomes in Bladder Cancer.
Cancer Discov. 2026 Feb 11:OF1. doi: 10.1158/2159-8290.CD-RW2026.
PubMed
Cancer Genomics Proteomics
- BARLAK BSR, Iskender B
Proteomic Signatures of Cellular Reprogramming in Bladder Cancer: Insights into
the Acquisition of Cancer Stem-like States and Phenotypic Plasticity.
Cancer Genomics Proteomics. 2026;23:300-321.
PubMed
Abstract available
Cancer Immunol Immunother
- JIANG Y, Li J, Yang Z, Ma M, et al
Multi-omics study on tumor-associated macrophages remodeling the tumor
microenvironment via the CXCL5-CXCR2 axis to drive immune escape in bladder
cancer.
Cancer Immunol Immunother. 2026;75:103.
PubMed
Abstract available
Cancer Manag Res
- WANG Q, Pei CS, Cao JY, Peng H, et al
Impact of Surgical Wait Time on Survival After Radical Cystectomy for
Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study.
Cancer Manag Res. 2026;18:583762.
PubMed
Abstract available
Cancer Med
- MANCIN S, Ferrara G, Palomares SM, Matteucci S, et al
Vitamin D and Bladder Cancer Risk: An Umbrella Review and Second Order
Meta-Analysis.
Cancer Med. 2026;15:e71672.
PubMed
Abstract available
Cancer Res
- GARCIA-RODRIGUEZ JL, Korsgaard U, Ahmadov U, Jarlstad Olesen MT, et al
Spatial Profiling of Circular RNAs in Cancer Reveals High Expression in Muscle
and Stromal Cells.
Cancer Res. 2023;83:3340-3353.
PubMed
Abstract available
Cancer Sci
- TIAN X, Liu Y, Mi Z, Liang Y, et al
CALR/HIF-1alpha Positive Feedback Loop Drives CALR Upregulation to Promote
EMT-Mediated Bladder Cancer Progression via ROS/AKT Axis.
Cancer Sci. 2026 Mar 5. doi: 10.1111/cas.70354.
PubMed
Abstract available
Cell Signal
- GUO X, Zhu C, Yin Z
A positive SPTBN2-FLI1 feedback axis promotes bladder cancer via PI3K/AKT
activation.
Cell Signal. 2026 Mar 4:112471. doi: 10.1016/j.cellsig.2026.112471.
PubMed
Abstract available
Clin Chim Acta
- KHAN A, Alanazi FJ, Ahmed S, Alzahrani AR, et al
Glycoprotein biomarkers for bladder cancer detection.
Clin Chim Acta. 2026;586:120938.
PubMed
Abstract available
Clin Exp Med
- AJALLI MM, Sansebli Y, Ekrami D, Alaeenejad F, et al
Immune checkpoint inhibitors in bladder cancer: from mechanistic insights to
emerging combination frontlines.
Clin Exp Med. 2026 Mar 5. doi: 10.1007/s10238-026-02098.
PubMed
Clin Genitourin Cancer
- DOMANSKI P, Hanusz K, Zapala L, Shah P, et al
Efficacy and Safety of Intravesical Gemcitabine and Docetaxel Combination Therapy
in Patients With Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer:
A Systematic Review and Meta-Analysis.
Clin Genitourin Cancer. 2026 Feb 11:102514. doi: 10.1016/j.clgc.2026.102514.
PubMed
Abstract available
Clin Nucl Med
- MAN X, Dong C, Dong A, Song X, et al
FDG PET/CT in Primary Mucosa-associated Lymphoid Tissue Lymphoma of the Bladder.
Clin Nucl Med. 2026 Jan 6. doi: 10.1097/RLU.0000000000006295.
PubMed
Abstract available
Clin Transl Med
- VAN CREIJ NCH, Tymoszuk P, Handle F, Seeber A, et al
Multi-omic profiling defines three distinct molecular subtypes of urothelial
carcinoma with implications for precision therapy.
Clin Transl Med. 2026;16:e70638.
PubMed
Abstract available
Crit Rev Oncol Hematol
- XU C, Zou W, Wang Y, Liu X, et al
Bladder-sparing treatment for muscle-invasive bladder carcinoma using immune
checkpoint inhibitors.
Crit Rev Oncol Hematol. 2023;191:104137.
PubMed
Abstract available
Cureus
- MIYAMOTO T, Miyake M, Nishimura N, Oda Y, et al
Immunogenic Tumor Cell Death Induced by Neoadjuvant Chemotherapy in Patients With
Muscle-Invasive Bladder Cancer: An Immunohistochemical Analysis.
Cureus. 2026;18:e102672.
PubMed
Abstract available
Curr Oncol
- HUANG J, Ojo A, Liaw B
Predictors of Response and Mechanisms of Resistance to Antibody Drug Conjugates
in Urothelial Carcinoma.
Curr Oncol. 2026;33:103.
PubMed
Abstract available
Curr Opin Urol
- GONZALEZ-PADILLA DA, Subiela JD, Guerrero-Ramos F, Pichler R, et al
Latest developments in urinary tumor DNA and its current clinical role in
urothelial bladder cancer and upper tract urothelial carcinoma.
Curr Opin Urol. 2026 Mar 4. doi: 10.1097/MOU.0000000000001373.
PubMed
Abstract available
Curr Probl Diagn Radiol
- PERUZZI V, Torresan S, Cortiula F, Fanelli M, et al
Unveiling the Potential of Venn Diagrams as a Helpful Tool for Clinical
Reasoning: An Illustrative Case-based Discussion.
Curr Probl Diagn Radiol. 2023;52:478-481.
PubMed
Abstract available
Diagn Cytopathol
- ORDOBAZARI A, Nikfar R, Zhao X, Davaro E, et al
Evaluating the Performance of the Paris System in Neobladder Cytology: The Role
of Cellularity and Volume Adequacy Criteria.
Diagn Cytopathol. 2026;54:299-306.
PubMed
Abstract available
- FARTIYAL JS, Rao M, Elhence PA, Nalwa A, et al
Comparison of Conventional Sediment Smears and Liquid-Based Cytology and Utility
of Cell Block Preparation in Urinary Cytology.
Diagn Cytopathol. 2026;54:285-292.
PubMed
Abstract available
Dis Markers
-
Correction to "KIF20A Affects the Prognosis of Bladder Cancer by Promoting the
Proliferation and Metastasis of Bladder Cancer Cells".
Dis Markers. 2026;2026:9804137.
PubMed
Abstract available
Discov Oncol
- CAO JY, Peng H, Wang GY, Chang PA, et al
IGF2BP3 promotes the muscle invasion of bladder cancer via PPARgamma dysregulation.
Discov Oncol. 2026 Mar 5. doi: 10.1007/s12672-026-04648.
PubMed
Eur J Med Chem
- ZHANG M, Wang K, Li G, Bao X, et al
Light-activated targeted degradation of VHL drug for selective tumor killing: A
novel strategy for precision therapy of bladder cancer.
Eur J Med Chem. 2026;309:118736.
PubMed
Abstract available
Eur Radiol
- WOO S, Luk L, Muglia VF, Briganti A, et al
VI-RADS quality score: development and proposal of a scoring system by the
American College of Radiology VI-RADS Steering Committee.
Eur Radiol. 2026;36:1093-1104.
PubMed
Abstract available
Eur Urol Oncol
- LIJNEN RAG, Ringia JB, Claps F, Vogel WV, et al
Diagnostic Value of Fluorine-18-fluorodeoxyglucose Positron Emission
Tomography/Computed Tomography in Staging Histological Subtypes of Invasive
Bladder Cancer.
Eur Urol Oncol. 2026 Mar 6:S2588-9311(26)00046-5. doi: 10.1016/j.euo.2026.
PubMed
Abstract available
- THU PHUNG TA, Weng R, Black PC, Dyrskjot L, et al
A Long Noncoding RNA-based Classifier for Identifying More Aggressive Low-grade
Ta Bladder Cancer with Elevated FGFR3 Activity.
Eur Urol Oncol. 2026 Feb 27:S2588-9311(26)00057.
PubMed
Abstract available
Expert Rev Anticancer Ther
- D'AGOSTINO E, Pirola M, Callegari V, Tonni E, et al
Future directions for antibody-drug conjugates in urothelial cancer.
Expert Rev Anticancer Ther. 2026;26:321-332.
PubMed
Abstract available
- KEANE KG, Redfern A, Lim J, Hayne D, et al
The role of gemcitabine-docetaxel in the management of NMIBC: a scoping review of
current status and future directions.
Expert Rev Anticancer Ther. 2026;26:333-344.
PubMed
Abstract available
- KEANE KG, Redfern A, Lim J, Hayne D, et al
The role of immune checkpoint inhibitors in the management of NMIBC: a scoping
review of current status and future direction.
Expert Rev Anticancer Ther. 2026;26:307-320.
PubMed
Abstract available
Folia Med (Plovdiv)
- OEY O, Tiong SS, Wong SL, Navadgi S, et al
Triple synchronous malignancies of the stomach, bladder and thyroid in a
previously treated prostate cancer patient: A Case Report.
Folia Med (Plovdiv). 2023;65:693-698.
PubMed
Abstract available
Fr J Urol
- TANGUY M, Armelle P, Sheik E, Nicolas I, et al
Real-World Data on Neoadjuvant Chemotherapy for Localized Muscle-Invasive Bladder
Cancer (2015-2024): A Single-Center Retrospective Study.
Fr J Urol. 2026 Mar 3:103093. doi: 10.1016/j.fjurol.2026.103093.
PubMed
Abstract available
- FORTIER A, Mokadem S, Saadi A, Gillibert A, et al
Does ureteroileal anastomosis technique (Bricker versus Wallace) influence benign
ureteroileal stricture occurrence on transileal diversion?
Fr J Urol. 2026;36:103078.
PubMed
Abstract available
Front Cell Infect Microbiol
- QI T, Yang W, Liu R, Deng D, et al
SWI/SNF-associated molecular subtypes reshape tumor microenvironmental features
and inform precision therapeutic strategies in bladder cancer.
Front Cell Infect Microbiol. 2026;16:1774929.
PubMed
Abstract available
Front Endocrinol (Lausanne)
- WANG X, Zhao J, Li Q, Chang J, et al
Disulfidptosis and androgenic cancers: from molecular mechanisms to clinical
applications and future translational research.
Front Endocrinol (Lausanne). 2026;17:1783929.
PubMed
Abstract available
Front Immunol
- CERBONE L, Roviello G, Calabro F, Taha T, et al
Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and
avelumab make a difference in a poor-prognosis scenario?
Front Immunol. 2026;17:1667155.
PubMed
Abstract available
Front Oncol
- TAN K, Quan X, Tan M, Han Z, et al
Metachronous multiple primary cancers involving pulmonary non-Hodgkin lymphoma
and bladder cancer: a case report.
Front Oncol. 2026;16:1734661.
PubMed
Abstract available
- LI Z, Wang G, Tan S, Wang Y, et al
Expression of ribosomal S6 kinase 4 in bladder cancer and its correlation with
clinicopathological features.
Front Oncol. 2026;16:1757293.
PubMed
Abstract available
- FENG R, Zhang J, Tao Y, Hou J, et al
Correction: Preoperative inflammation-based immune prognostic nomogram in bladder
cancer: a multicenter study.
Front Oncol. 2026;16:1787982.
PubMed
Abstract available
- BLUMENFELD P, Levy D, Hillman Y, Feldman J, et al
Daily artificial intelligence-assisted adaptive small margin radiotherapy during
trimodal therapy of muscle-invasive bladder cancer.
Front Oncol. 2026;16:1729810.
PubMed
Abstract available
Future Med Chem
- WEI G, Fan ZH, Huang RZ, Wei Y, et al
Design, synthesis and antitumor activity evaluation of 1,4-naphthoquinone-benzene
sulfonamide hybrids.
Future Med Chem. 2026;18:637-648.
PubMed
Abstract available
Hum Pathol
- COLLINS K, Gupta S, Cheng L
Updates in bladder and prostate pathology: Diagnostic consensus and clinical
relevance.
Hum Pathol. 2026;169:106018.
PubMed
Abstract available
IJU Case Rep
- ITO K, Yamashita R, Kasai S, Sakura Y, et al
A Case of Unexpected Peritoneal Carcinomatosis From Colon Cancer Detected After
Robot-Assisted Radical Cystectomy for Advanced Bladder Cancer.
IJU Case Rep. 2026;9:e70155.
PubMed
Abstract available
- IMAI K, Masuda N, Hazama T, Hosomi T, et al
Invasive Bladder Cancer With Peritoneal Invasion and Rectal Involvement Causing
Rectal, Bilateral Ureteral, and Common Bile Duct Obstruction Without a
Retroperitoneal Mass: A Case Report.
IJU Case Rep. 2026;9:e70157.
PubMed
Abstract available
Int Immunopharmacol
- GAO X, Liu J, Deng D, Xiao J, et al
The ZNF737-CXCL10 axis drives immune exclusion and resistance to anti-PD-1
therapy in bladder cancer.
Int Immunopharmacol. 2026;175:116443.
PubMed
Abstract available
Int J Med Sci
- HUANG Z, Cao X, Yan Y, Li H, et al
Integrative analysis of the PSMA family identifies PSMA6 as an adverse prognostic
biomarker promoting bladder cancer cell proliferation.
Int J Med Sci. 2026;23:986-1001.
PubMed
Abstract available
Int J Surg Pathol
- RIZKALLA CN, Tretiakova M, Williamson SR, Akgul M, et al
Overlapping Morphologic and Immunophenotypic Features of Plasmacytoid Urothelial
Carcinoma and Urothelial Carcinoma With Osteoclast-Like Giant Cells.
Int J Surg Pathol. 2026;34:309-314.
PubMed
Abstract available
Int Urol Nephrol
- ZHENG Q, Liao E, Chen D, Shan G, et al
Bladder cancer organoids: bridging pathological features and drug response for
precision oncology.
Int Urol Nephrol. 2026 Mar 8. doi: 10.1007/s11255-026-05081.
PubMed
Abstract available
- THAKKER PU, Refugia JM, Casals R, Able C, et al
Stent-free rates in cutaneous ureterostomy urinary diversion after radical
cystectomy.
Int Urol Nephrol. 2023;55:2809-2814.
PubMed
Abstract available
Investig Clin Urol
- KUROBE M, Ogawa T, Satoh Y, Yamamoto M, et al
Near infrared ray-guided partial cystectomy using da Vinci Firefly((R)) technology
and intraoperative cystoscopy for urachal cyst, suspected of urachal tumor.
Investig Clin Urol. 2026;67:178-185.
PubMed
Abstract available
- YOON SG, Park TY, Jin HJ, Noh TI, et al
Long-term oncologic outcomes of robot-assisted radical cystectomy: Prognostic
indicators and complication profiles from a high-volume single-surgeon series.
Investig Clin Urol. 2026;67:148-161.
PubMed
Abstract available
- CHOI SY, Yang YJ, Min KC, Lee YS, et al
Diagnostic performance of narrow-band imaging and photodynamic diagnosis compared
to white light cystoscopy for non-muscle invasive bladder cancer: A network
meta-analysis of randomized trials.
Investig Clin Urol. 2026;67:131-139.
PubMed
Abstract available
J Biochem Mol Toxicol
- LU S, Zhang X, Cai Z, Xi Z, et al
Identification of novel lncRNA prognostic biomarkers and their associated ceRNAs
in bladder urothelial carcinoma.
J Biochem Mol Toxicol. 2023;37:e23441.
PubMed
Abstract available
J Cancer Policy
- BENCINA G, Ruiz RA, Bencina B
Evaluating the economic burden of bladder cancer in 32 European countries using a
value of a statistical life year framework.
J Cancer Policy. 2026;48:100728.
PubMed
Abstract available
J Clin Invest
- MEEKS JJ
The changing landscape of urothelial carcinoma: on the edge of a paradigm shift.
J Clin Invest. 2026;136:e202079.
PubMed
Abstract available
J Clin Oncol
- KAMAT AM, Hensley PJ, Maiorano BA, Li R, et al
Bacillus Calmette-Guerin (BCG) and Beyond: Is Systemic Immunotherapy for
BCG-Naive Non-Muscle-Invasive Bladder Cancer Progress or Overreach?
J Clin Oncol. 2026 Mar 2:JCO2502670. doi: 10.1200/JCO-25-02670.
PubMed
J Coll Physicians Surg Pak
- LI J, He Y, Wu S
Predictors of Residual Tumour in Non-Muscle-Invasive Bladder Cancer Following
Repeat Transurethral Resection: A Meta-Analysis.
J Coll Physicians Surg Pak. 2026;36:87-94.
PubMed
Abstract available
J Racial Ethn Health Disparities
- DENG Z, Li M, Li J, Jung M, et al
Disparities in Cancer and Cardiovascular Disease Mortality Among Asian Americans
Diagnosed with Urologic Cancer.
J Racial Ethn Health Disparities. 2026;13:1555-1571.
PubMed
Abstract available
J Surg Oncol
- MENGYAN J, Jun Q, Wen L, Tingting P, et al
Research Progress on Financial Toxicity in Bladder Cancer Patients.
J Surg Oncol. 2026 Mar 8. doi: 10.1002/jso.70201.
PubMed
Abstract available
J Urol
- UDEDIBIA E, Solosky K, Macdonald EJ, Gaines J, et al
Critical Analysis of the AUA 2020/2025 Microscopic Hematuria Guidelines to
Predict Urothelial but Not Renal Cortical Neoplasms and Validation of the
Individual Clinical Components in Risk Stratification for Urothelial Neoplasms
but Not Renal Cortical
J Urol. 2026;215:441-449.
PubMed
Abstract available
J Vet Intern Med
- BURTZ M, Boss MK, Leary D, Martin TW, et al
Radiation therapy as a treatment for urinary obstruction secondary to urothelial
carcinoma in dogs.
J Vet Intern Med. 2026;40:aalaf093.
PubMed
Abstract available
JCO Oncol Pract
- WONG R, Matulewicz RS, Talwar R, Goldstein AO, et al
Temporal Association of US Tobacco Taxation on Smoking Attributable Bladder
Cancer Mortality and Disability-Adjusted Life Years.
JCO Oncol Pract. 2026 Mar 2:OP2500780. doi: 10.1200/OP-25-00780.
PubMed
Abstract available
Jpn J Clin Oncol
- YAMASHITA S, Wada T, Deguchi R, Mashima N, et al
Prognostic significance of pre-treatment albumin-bilirubin grade in metastatic
urothelial carcinoma receiving pembrolizumab.
Jpn J Clin Oncol. 2023;53:845-850.
PubMed
Abstract available
Lancet Oncol
- NECCHI A, Maiorano BA, de Jong JJ, Proudfoot JA, et al
Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant
pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a
single-arm, phase 2 study.
Lancet Oncol. 2026 Feb 27:S1470-2045(26)00050.
PubMed
Abstract available
Magy Onkol
- HERMANN-VARADI M
[Prediction of immune checkpoint inhibitor therapy in urothelial carcinoma:
integrated analysis of molecular patterns and clinical factors].
Magy Onkol. 2026;70:85-87.
PubMed
Abstract available
- PULUGOR GD, Galdi A, Varga L, Jorgo K, et al
[Daily online adaptive irradiation of bladder tumors with individualized safety
margin creation].
Magy Onkol. 2026;70:23-31.
PubMed
Abstract available
Mol Genet Genomics
- HE J, Jiang Z, Peng S, Peng L, et al
Single-cell transcriptomic profiling combined with Mendelian randomization
illuminates molecular drivers of bladder cancer.
Mol Genet Genomics. 2026;301:50.
PubMed
Abstract available
Nat Rev Clin Oncol
- SIDAWAY P
Enfortumab vedotin plus pembrolizumab effective in patients with resectable
bladder cancer.
Nat Rev Clin Oncol. 2026 Mar 2. doi: 10.1038/s41571-026-01139.
PubMed
NPJ Digit Med
- HUANG J, Hu H, Sun M, Wu W, et al
A domain-adaptive deep contrastive network for magnetic resonance imaging-driven
bladder cancer classification.
NPJ Digit Med. 2026 Mar 3. doi: 10.1038/s41746-026-02499.
PubMed
Abstract available
Pathol Res Pract
- CUADRA JDP, Perez MA, Gonzalez-Peramato P, Sanz J, et al
PD-L1 expression across urothelial carcinoma subtypes: A multicenter comparison
of 22C3 and SP142 for clinical decision-making in the immunotherapy era.
Pathol Res Pract. 2026;281:156372.
PubMed
Abstract available
Patient
- MASON B, Eccleston A, Ayala-Nunes L, Hauber B, et al
Incorporating the Patient Voice into Attribute and Level Selection for a
Preference Study: A Qualitative Study in Non-Muscle Invasive Bladder Cancer.
Patient. 2026 Mar 11. doi: 10.1007/s40271-026-00804.
PubMed
Abstract available
Pediatr Dev Pathol
- KIMBALL J, Steele J, Vargas SO, Hirsch M, et al
BK Polyomavirus-Associated Kidney and Bladder Carcinomas Following Heart and Lung
Transplantation in Childhood.
Pediatr Dev Pathol. 2026;29:128-135.
PubMed
Abstract available
PeerJ
- NIE Q, Jiang M, Wan S, Xi M, et al
Neuro-immune-related gene signatures define molecular subtypes and prognostic
score in bladder cancer with SERPINE2 as a potential therapeutic target.
PeerJ. 2026;14:e20917.
PubMed
Abstract available
Phytomedicine
- SONG YS, Liu CK, Jiang WS, Liu J, et al
Targeting GRB2 with Polyphyllin H overcomes PIKFYVE inhibitor resistance in
bladder cancer by blocking Akt-SREBP1-SCD1 pathway.
Phytomedicine. 2026;154:158011.
PubMed
Abstract available
Quant Imaging Med Surg
- HAO Z, Zhu L, Ding J, Jin Q, et al
bp-VI-RADS combined with normalized apparent diffusion coefficient enhances
diagnostic efficacy for muscle-invasive bladder cancer.
Quant Imaging Med Surg. 2026;16:244.
PubMed
Abstract available
Sci Rep
- LI Z, Yu Y, Liu F, Wu Y, et al
Suppression of LTBP1 enhances the sensitivity of bladder cancer to cisplatin.
Sci Rep. 2026 Mar 13. doi: 10.1038/s41598-026-42815.
PubMed
Abstract available
- LODEWIJK I, Rubio C, Eriksson P, Reina IA, et al
CD44v6 is associated with tumor aggressiveness and chemoresistance in bladder
cancer.
Sci Rep. 2026 Mar 11. doi: 10.1038/s41598-026-42566.
PubMed
- QIN Z, Zhou H, Hu Y, Xiong X, et al
Survival prediction for bladder cancer using multimodal data with quantum neural
networks and transformer architectures.
Sci Rep. 2026 Mar 7. doi: 10.1038/s41598-026-42047.
PubMed
Abstract available
Se Pu
- LIU S, Wang M, Wang W
[Analysis of urine biomarkers in urothelial carcinoma based on untargeted
metabolomics].
Se Pu. 2026;44:329-337.
PubMed
Abstract available
Semin Nucl Med
- MENA E, Lindenberg L, Heng S, Choyke PL, et al
Advances and challenges of PET imaging in bladder cancer-An update and future
trends.
Semin Nucl Med. 2026 Mar 2:S0001-2998(26)00046.
PubMed
Abstract available
Surg Oncol
- SONG SH, Park JH, Lee S, Jeong SH, et al
Oncological outcomes of concurrent nephroureterectomy during radical cystectomy:
A propensity score-matched analysis with multivariable adjustment from Korean
multicenter database.
Surg Oncol. 2026;65:102362.
PubMed
Abstract available
Toxicol Appl Pharmacol
- YAN H, Yin C, Xu F, Li R, et al
Unraveling the connection between PFOA and bladder cancer: A study integrating
network toxicology, molecular docking, and experimental validation.
Toxicol Appl Pharmacol. 2026;511:117784.
PubMed
Abstract available
Transl Androl Urol
- LIANG S, Liu H, Su Q, Li X, et al
Machine learning identifies a DNA repair-related risk model for bladder cancer
and functionally characterizes ZWINT as a potential oncogenic factor.
Transl Androl Urol. 2026;15:46.
PubMed
Abstract available
- LIU J, Tang X, Cui Y, Yang X, et al
Development and validation of a gemcitabine sensitivity-related long noncoding
RNA signature for predicting the prognosis and subtypes of bladder cancer.
Transl Androl Urol. 2026;15:60.
PubMed
Abstract available
Urol Oncol
- MOINARD-BUTOT F, Barbe-Richaud JB, Baudry E, Pierard L, et al
Real-world treatment sequences and overall survival in metastatic bladder cancer:
The STATES-Bladder study.
Urol Oncol. 2026;44:111036.
PubMed
Abstract available
Urologia
- SHUKLA A, Hiralal, Raj H, Surekha S, et al
Diagnostic accuracy and reliability of VI-RADS in assessing muscle invasion in
bladder cancer: Insight from a prospective tertiary care study.
Urologia. 2026 Mar 13:3915603261429445. doi: 10.1177/03915603261429445.
PubMed
Abstract available
Urologie
- BOLENZ C, Heidenreich A
[From limited options to individualized strategies: advances in the treatment of
bladder cancer].
Urologie. 2026;65:239-241.
PubMed
- GAISA NT, Reis H, Heidenreich A
[Diagnosis and treatment of urothelial carcinoma of the bladder with divergent
histology].
Urologie. 2026;65:278-287.
PubMed
Abstract available
- KOHLER J, Rodler S, Andersson J, Juptner M, et al
[Innovative imaging techniques for urothelial carcinoma].
Urologie. 2026;65:242-249.
PubMed
Abstract available
- NIEGISCH G, Zschabitz S, Eckstein M, Klumper N, et al
[From nontargeted to precision oncology: predictive biomarkers and targeted
therapies in advanced urothelial carcinoma].
Urologie. 2026;65:271-277.
PubMed
Abstract available
- SCHNEIDEWIND L, Kiss B, Arnold N, Kranz J, et al
[Gender-specific differences in outcome and survival in early cystectomy :
Systematic review].
Urologie. 2026;65:300-307.
PubMed
Abstract available
- GIESE M, Butea-Bocu M, Huber J, Groeben C, et al
[Prehabilitation prior to radical cystectomy].
Urologie. 2023;62:1034-1040.
PubMed
Abstract available
- MENDES WEFELNBERG M, Reimer N, Baumann FT
[Exercise therapy in prehabilitation : Current findings in urology].
Urologie. 2023;62:1011-1016.
PubMed
Abstract available
World J Gastrointest Pharmacol Ther
- WISHAHI M
Gut microbiotas attributed to disorders and diseases of the gastrointestinal
tract, colorectal cancer, bladder cancer: Geographical factors, inflammation,
metabolic toxic.
World J Gastrointest Pharmacol Ther. 2026;17:115573.
PubMed
Abstract available
FAQ
